This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Zoetis Inc. came into existence following Pfizer’s decision to spin off its animal health business. he company is a leader in the discovery, development, manufacture and commercialization of animal health medicines, vaccines and diagnostic products with a focus on both livestock and companion animals. Zoetis has a diversified business, which caters to eight core species — cattle, swine, poultry, fish and sheep (collectively, livestock) and dogs, cats and horses (collectively, companion animals).
Zoetis (ZTS) in Focus: Stock Moves 6.9% Higher
by Zacks Equity Research
Zoetis (ZTS) saw a big move last session, as its shares jumped nearly 7% on the day, amid huge volumes.
Zoetis (ZTS) Tops Q3 Earnings and Revenue Estimates
by Zacks Equity Research
Zoetis (ZTS) delivered earnings and revenue surprises of 23.60% and 10.90%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?
Why Earnings Season Could Be Great for Zoetis (ZTS)
by Zacks Equity Research
Zoetis (ZTS) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
Big Drug/Biotech Stock Q3 Earnings on Nov 5: REGN, BMY & More
by Kinjel Shah
Let us take a look at four big drug/biotech companies, REGN, BMY, INCY & ZTS, which are gearing up for their earnings release.
Zimmer Biomet (ZBH) to Report Q3 Earnings: What's in Store?
by Zacks Equity Research
Zimmer Biomet's (ZBH) Dental product volumes are expected to have declined significantly in the third quarter due to the extremely elective nature of the products.
Zoetis (ZTS) to Report Q3 Earnings: What's in the Cards?
by Zacks Equity Research
Zoetis (ZTS) will provide updates on earnings, revenues and other pipeline developments when its releases third-quarter 2020 results.
Pacira's (PCRX) Q3 Earnings Top Estimates, Revenues Rise Y/Y
by Zacks Equity Research
Pacira's (PCRX) both bottom and the top line surpass estimates in Q3. Exparel sales rise year over year.
Zoetis (ZTS) Expected to Beat Earnings Estimates: What to Know Ahead of Q3 Release
by Zacks Equity Research
Zoetis (ZTS) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
GRFS vs. ZTS: Which Stock Is the Better Value Option?
by Zacks Equity Research
GRFS vs. ZTS: Which Stock Is the Better Value Option?
The Zacks Analyst Blog Highlights: Netflix, Lockheed, Zoetis, ITUB and Moderna
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Netflix, Lockheed, Zoetis, ITUB and Moderna
Top Analyst Reports for Netflix, Lockheed Martin & Zoetis
by Mark Vickery
Today's Research Daily features new research reports on 12 major stocks, including Netflix (NFLX), Lockheed Martin (LMT) and Zoetis (ZTS).
Is Zoetis (ZTS) Stock Outpacing Its Medical Peers This Year?
by Zacks Equity Research
Is (ZTS) Outperforming Other Medical Stocks This Year?
Why Zoetis (ZTS) is Poised to Beat Earnings Estimates Again
by Zacks Equity Research
Zoetis (ZTS) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
JAZZ vs. ZTS: Which Stock Is the Better Value Option?
by Zacks Equity Research
JAZZ vs. ZTS: Which Stock Is the Better Value Option?
Top Stock Reports for Anheuser-Busch, Gilead & Canadian National
by Sheraz Mian
Today's Research Daily features new research reports on 16 major stocks, including Anheuser-Busch InBev (BUD), Gilead Sciences (GILD) and Canadian National Railway (CNI).
JAZZ vs. ZTS: Which Stock Is the Better Value Option?
by Zacks Equity Research
JAZZ vs. ZTS: Which Stock Is the Better Value Option?
Why Is Zoetis (ZTS) Down 2.5% Since Last Earnings Report?
by Zacks Equity Research
Zoetis (ZTS) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
The Zacks Analyst Blog Highlights: Intel, Coca-Cola, Starbucks, Caterpillar and Zoetis
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Intel, Coca-Cola, Starbucks, Caterpillar and Zoetis
Top Analyst Reports for Intel, Coca-Cola & Starbucks
by Sheraz Mian
Today's Research Daily features new research reports on 16 major stocks, including Intel (INTC), Coca-Cola (KO) and Starbucks (SBUX).
JAZZ vs. ZTS: Which Stock Should Value Investors Buy Now?
by Zacks Equity Research
JAZZ vs. ZTS: Which Stock Is the Better Value Option?
Top Stock Reports for Tesla, Disney & PepsiCo
by Sheraz Mian
Today's Research Daily features new research reports on 16 major stocks, including Tesla (TSLA), The Walt Disney Company (DIS) and PepsiCo (PEP).
Zoetis' (ZTS) Q2 Earnings and Revenues Surpass Estimates
by Zacks Equity Research
Zoetis (ZTS) beats both earnings and sales estimates in the second quarter of 2020.
Zoetis (ZTS) Q2 Earnings and Revenues Beat Estimates
by Zacks Equity Research
Zoetis (ZTS) delivered earnings and revenue surprises of 34.85% and 13.88%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?
Zoetis (ZTS) to Report Q2 Earnings: What's in the Cards?
by Zacks Equity Research
Zoetis (ZTS) will provide financial updates when it reports second-quarter 2020 results.
Zoetis (ZTS) Expected to Beat Earnings Estimates: Should You Buy?
by Zacks Equity Research
Zoetis (ZTS) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.